Prothena to Participate in Jefferies Healthcare Conference

Rhea-AI Summary

Prothena Corporation plc (NASDAQ:PRTA) announced that its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 8:30 AM ET. The event will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days afterward. Prothena focuses on developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. The company is advancing a robust pipeline targeting conditions like AL amyloidosis and Alzheimer's disease.

DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday June 8, 2022 at 8:30 AM ET.

A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:
Media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, media@prothena.com

Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com

FAQ

When will Prothena participate in the Jefferies Healthcare Conference?

Prothena Corporation will participate in the Jefferies Healthcare Conference on June 8, 2022, at 8:30 AM ET.

How can I access the Prothena fireside chat webcast?

The webcast of Prothena's fireside chat can be accessed through the investor relations section of their website.

What is Prothena's focus in biotechnology?

Prothena focuses on developing investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases.

What diseases are included in Prothena's therapeutic pipeline?

Prothena’s pipeline includes treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, and Parkinson’s disease.

Where can I find more information about Prothena's research?

More information about Prothena's research and pipeline can be found on their official website.